window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 29, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

cell and gene therapy

  • Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain

    Lonza to acquire Redberry to expand rapid microbiology testing for pharmaceutical quality control

    Lonza has signed an agreement to acquire Redberry, a French [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    BBG Advanced Therapies and CELLforCURE partner to provide transatlantic ATMP manufacturing solutions

    BBG Advanced Therapies (BBGAT), a subsidiary of BioBridge Global and [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    Vitalant launches national service hubs to expand patient access to cell and gene therapies

    Vitalant has launched a national hub-and-spoke model to expand patient [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    EG 427 reports strong initial results for DNA therapy in neurogenic bladder trial

    EG 427 has released encouraging first clinical data from its [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    eXmoor Pharma and Siam Bioscience partner to expand cell and gene therapy services in Southeast Asia

    eXmoor Pharma and Siam Bioscience have announced a strategic partnership [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    Chrysalis appoints Adam Bartley as chief operating officer

    Chrysalis, a provider of GMP cleanroom hosting and support services [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory

    Vitalant and UPMC expand partnership to advance cell and gene therapy initiatives

    Vitalant, a national blood and biotherapies provider, is expanding its [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Opinion & Events

    Anocca raises SEK 440M to advance TCR-T cell therapies into clinical development

    Swedish clinical-stage biotech Anocca AB has secured approximately SEK 440 [...]

    May 5, 2026
  • Advanced Therapies,Therapeutic Areas

    Broken String renews NIST gene editing safety push with INDUCE-seq technology

    Broken String Biosciences has reaffirmed its commitment to supporting the [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Therapeutic Areas

    Novotech report explores how in-vivo CAR-T could transform cell therapy access and costs

    A new whitepaper from Novotech has outlined how in-vivo CAR-T [...]

    May 5, 2026
Previous123Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Phase 2 trial begins for fetal growth restriction therapy with no approved drug treatments available
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Oral GLP-1 candidate CX11 achieves 11.5% weight loss in US Phase 2 obesity trial
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
  • NICE recommends cemiplimab for recurrent or metastatic cervical cancer
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top